Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Crocal
- Development stage
- Unknown
- Lead developer
- Croise Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Crocal is a multi-ingredient nutritional supplement developed by Croise Pharma. It is formulated as an oral tablet containing calcium citrate, magnesium, zinc, and vitamin D3 (cholecalciferol). Crocal is primarily indicated for the treatment and prevention of nutritional deficiencies, bone disorders such as osteoporosis, osteomalacia, and rickets, and to support bone growth, development, and strength. It is also used to maintain adequate calcium levels in pregnant, nursing, or postmenopausal women.
- Brand names
- CrocalCrocal Plus
- Other names
- calcium citrate + calcitriol + magnesium + zinccalcium citrate + cholecalciferol + magnesium + zinc
02
Targets
CaSR (Extracellular calcium-sensing receptor)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on Crocal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Crocal.